Bicara Therapeutics reports Q4 net loss $21M, cash $489.7M; pivotal Phase 2/3 trial dosing started

Bicara Therapeutics Inc.

Net loss $21.0M in Q4 2024, $68.0M full year; vs $12.4M and $52.0M in 2023.
Cash and equivalents $489.7M as of Dec 31, 2024, up from $230.4M; funds operations into first half 2029.
First patients dosed in February 2025 in FORTIFI-HN01, pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC.
Updated Phase 1/1b data for ficerafusp alfa in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting.
Three abstracts on ficerafusp alfa accepted for AACR 2025, including monotherapy in cSCC and preclinical lung cancer data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.